版本:
中国

BRIEF-Eiger reports additional positive phase 2 results from multiple-ascending dose study of exendin 9-39

June 12 Eiger Biopharmaceuticals Inc

* Eiger reports additional positive phase 2 results from multiple-ascending dose study of exendin 9-39 in post-bariatric hypoglycemia patients at american diabetes association meeting in san diego

* Sc exendin 9-39 liquid and lyophilized formulations were well tolerated with no related adverse events

* Sc exendin 9-39 liquid and lyophilized formulations reduced postprandial hyperinsulinemic hypoglycemia

* Sc exendin 9-39 liquid and lyophilized formulations reduced hypoglycemic symptoms Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐